XERIS PHARMACEUTICALS
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris�... � platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.
XERIS PHARMACEUTICALS
Industry:
Biotechnology Diabetes Health Care Pharmaceutical Therapeutics
Founded:
2005-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.xerispharma.com
Total Employee:
101+
Status:
Active
Contact:
844-445-5704
Total Funding:
289.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Tag Manager Amazon IPv6 COVID-19 ASP.NET Amazon Virginia Region
Similar Organizations
9 Meters Biopharma
9 Meters Biopharma is a gastrointestinal platform company focusing on patients with rare disorders and unmet needs.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Altamira Therapeutics
Altamira Therapeutics develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company that is driving the future of cellular immuno-oncology (IO).
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Cure Pharmaceutical
Cure Pharmaceutical is a specialty pharmaceutical and bioscience company, develops drug formulation and delivery technologies.
Evecxia Therapeutics
Evecxia Therapeutics is a pharmaceutical company that is dedicated to realizing the therapeutic potential of 5-hydroxytryptophan.
Exscientia
Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
G.I. Windows
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology.
Interius BioTherapeutics
Interius BioTherapeutics is a biopharmaceutical company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.
MediGene
MediGene is a company that specializes in biotechnology specifically in the treatment of cancer.
NewBridge Pharmaceuticals
Newbridge Pharmaceuticals is a pharmaceutical and medical device company engaged in developing oncology and supportive care products.
Noema Pharma
Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Reneo Pharmaceuticals
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Seagen
Seagen is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuCâ„¢ platform.
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Advisors List
Board_member
2018-04-01
Advisor
Board_member
2018-05-01
Board_member
Board_member
Board_member
2017-01-01
Board_member
2017-09-01
Current Employees Featured
Paul R Edick Chairman & CEO @ Xeris Pharmaceuticals
Chairman & CEO
2017-01-01
Kevin McCulloch SVP, Global Operations & Business Development @ Xeris Pharmaceuticals
SVP, Global Operations & Business Development
2018-10-01
John Shannon Chief Operating Officer @ Xeris Pharmaceuticals
Chief Operating Officer
2017-03-01
Christina Kline Vice President, Marketing @ Xeris Pharmaceuticals
Vice President, Marketing
2021-06-01
Steven Prestrelski Chief Scientific Officer @ Xeris Pharmaceuticals
Chief Scientific Officer
2011-01-01
Kenneth Johnson Senior Vice President @ Xeris Pharmaceuticals
Senior Vice President
Beth Hecht Senior Vice President, General Counsel & Corporate Secretary @ Xeris Pharmaceuticals
Senior Vice President, General Counsel & Corporate Secretary
2018-01-01
Allison Wey Senior Vice President of Investor Relations and Corporate Communications @ Xeris Pharmaceuticals
Senior Vice President of Investor Relations and Corporate Communications
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-05-24 | Strongbridge Biopharma | Strongbridge Biopharma acquired by Xeris Pharmaceuticals | 267 M USD |
Investors List
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Xeris Pharmaceuticals
Deerfield
Deerfield investment in Post-IPO Equity - Xeris Pharmaceuticals
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Xeris Pharmaceuticals
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Xeris Pharmaceuticals
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Xeris Pharmaceuticals
Merieux Developpement
Merieux Developpement investment in Series C - Xeris Pharmaceuticals
Wild Basin Investments
Wild Basin Investments investment in Series C - Xeris Pharmaceuticals
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Xeris Pharmaceuticals
Palmetto Partners
Palmetto Partners investment in Series C - Xeris Pharmaceuticals
Asahi Kasei
Asahi Kasei investment in Series C - Xeris Pharmaceuticals
Official Site Inspections
http://www.xerispharma.com Semrush global rank: 2.64 M Semrush visits lastest month: 6.49 K
- Host name: a23-212-250-17.deploy.static.akamaitechnologies.com
- IP address: 23.212.250.17
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Xeris Pharmaceuticals"
About Us - Xeris Biopharma Holdings, Inc.
Dr. Sherman also served on the Board of Directors of Strongbridge prior to its acquisition by Xeris Pharmaceuticals, Inc in 2021. Additionally, Dr. Sherman served previously on the Board of …See details»
Leadership - Xeris Biopharma Holdings, Inc.
Ms. Halkuff has held numerous senior-level commercial and marketing positions over 20 years, most recently as Chief Commercial Officer at TherapeuticsMD, Prior TherapeuticsMD, she …See details»
Xeris Biopharma - Crunchbase Company Profile & Funding
Contact Email info@xerispharma.com Phone Number 844-445-5704 Xeris Biopharma is a specialty pharmaceutical company leveraging its novel formulation technology platforms to …See details»
Xeris Pharmaceuticals, Inc. | LinkedIn
Xeris Pharmaceuticals, Inc. | 22,307 followers on LinkedIn. We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing …See details»
Xeris Biopharma Company Profile | Management and Employees …
Smith@xerispharma.com: Xeris Biopharma Top Competitors. Company Employees Revenue Top technologies; UroGen Pharma. 200: $85 M: Marinus Pharmaceuticals. 165: $30.3 M: Eagle …See details»
Xeris Biopharma Announces CEO Succession Plan
Successful commercial organization with over 400 employees, three marketed products, and the underlying technologies to continue advancing both our internal and partnered pipelines, said …See details»
Xeris Biopharma Holdings Company Description - Stock Analysis
6 days ago Company profile for Xeris Biopharma Holdings, Inc. (LON:0A8E) with a description, list of executives, contact details and other key facts.See details»
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
Feb 24, 2025 Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire. CHICAGO--(BUSINESS WIRE)--Feb. 24, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: …See details»
Xeris Pharmaceuticals - Overview, News & Similar companies
Jul 8, 2024 www.xerispharma.com. Revenue $171.4 Million. Stock Symbol XERS. Industry Pharmaceuticals Healthcare . Most Recent Scoops. Jul 8 2024. Left Company. Jul 8 2024. …See details»
Xeris Biopharma Holdings, Inc. (XERS) Company Profile & Overview
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable …See details»
Xeris Pharmaceuticals Company Profile | Management and
SQL International Organization for Standardization . CSS World Wide Web Consortium . PHP PHP . Other Communication and Collaboration Software (4 Technologies) ...See details»
News Release - Xeris Biopharma Holdings, Inc.
Gvoke ®, Gvoke HypoPen ®, XeriSol TM, XeriJect ®, Xeris Pharmaceuticals ®, Ogluo ®, Keveyis ®, Recorlev ®,Gvoke HypoPen 2-Pack TM, XerisCareConnection TM, PPP MentorConnect …See details»
Xeris Pharmaceuticals, Inc. Information - RocketReach
How many people are employed at Xeris Pharmaceuticals, Inc.? 397 people are employed at Xeris Pharmaceuticals, Inc..See details»
Xeris Pharmaceuticals - Craft
Oct 29, 2024 Xeris Pharmaceuticals has 5 employees at their 1 location and $20.16 m in annual revenue in FY 2020. See insights on Xeris Pharmaceuticals including office locations, …See details»
News Release - ir.xerispharma.com
Mar 6, 2025 Conference call and webcast at 8:30am ET. CHICAGO--(BUSINESS WIRE)--Feb. 27, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented …See details»
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply ...
Up to $71 million in time- and milestone-based payments, plus royalties on sales . Agreement covers 32 countries. First launch expected in Q4 2021 in UK. CHICAGO--(BUSINESS WIRE)- …See details»
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year …
Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year. Recorlev® revenue more than doubled versus prior year and grew 28% in …See details»
Xeris Biopharma Enters Into an Exclusive Worldwide License …
Jan 10, 2024 CHICAGO--(BUSINESS WIRE)--Jan. 10, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving …See details»
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
Mar 6, 2025 Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million. Year-end 2024 cash position expected to be over $71 million, …See details»
News Release - xerispharma.com
3 days ago First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market American Regent to commercialize GVOKE VialDx ™ Availability is …See details»